Results of a world-first phase 3 trial for secondary progressive multiple sclerosis (MS), led by UCL researchers, have shown that the commonly used high-cholesterol drug simvastatin cannot slow disability progression.
Clinical trial: Cholesterol drug ineffective for treatment of multiple sclerosis
-
HighlightsFree Dark Web Monitoring Stamps the $17 Million Credentials Markets
-
HighlightsSmart buildings: What happens to our free will when tech makes choices for us?
-
AppsScreenshots have generated new forms of storytelling, from Twitter fan fiction to desktop film
-
HighlightsDarknet markets generate millions in revenue selling stolen personal data, supply chain study finds
-
SecurityPrivacy violations undermine the trustworthiness of the Tim Hortons brand
-
Featured HeadlinesWhy Tesla’s Autopilot crashes spurred the feds to investigate driver-assist technologies – and what that means for the future of self-driving cars
